UNIGE document Scientific Article
previous document  unige:98377  next document
add to browser collection

Quels espoirs pour l’hépatite delta ?

Published in Revue médicale suisse. 2016, vol. 12, no. 528, p. 1415-1418
Abstract Hepatitis D or delta is a chronic liver disease globally reaching 15‑20M people. Its agent, hepatitis D virus (HDV) requires the presence of hepatitis B virus (HBV) to complete its life cycle. It represents one of the most severe forms of viral hepatitis. Current therapy with pegylated interferon alpha leads to viral eradication only in 25 % of cases. New treatments targeting the virus life cycle are sought. For example Myrcludex-B, which inhibits the entry into hepatocytes, lonafarnib which prevents the assemblage of the viral particle and the molecule REP 2139 which, among other unclear mechanisms, impedes the exit of the virus. This allows considering a better management of a condition for which there is currently no satisfactory treatment.
PMID: 28675280
Full text
Article (Published version) (936 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research groups Etudes et traitement de l'hépatite C et B (554)
Physiopathologie de la pancréatite aiguë (601)
(ISO format)
GUGLIELMI, Stefano, FROSSARD, Jean-Louis, NEGRO, Francesco. Quels espoirs pour l’hépatite delta ?. In: Revue médicale suisse, 2016, vol. 12, n° 528, p. 1415-1418. https://archive-ouverte.unige.ch/unige:98377

229 hits

1 download


Deposited on : 2017-11-01

Export document
Format :
Citation style :